A highlight from the LUPUS 2014 meeting: Eight great ideas

Lupus Science and Medicine

Volumn 2, Issue 1, 2015, Pages

  Buyon, Jill P ^a   Cohen, Phillip ^b   Merrill, Joan T ^c   Gilkeson, Gary ^d   Kaplan, Mariana ^e   James, Judith ^c   McCune, W Joseph ^f   Bernatsky, Sasha ^g   Elkon, Keith ^h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; HYDROXYCHLOROQUINE; INFLAMMASOME; MEPACRINE; PROTEIN S;

ADAPTIVE IMMUNITY; APOPTOSIS; ASYMPTOMATIC DISEASE; AUTOIMMUNITY; CANADA; CARDIOVASCULAR RISK; CELL COMMUNICATION; CELL DEATH; CELL FUNCTION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; EMERGENCY WARD; HUMAN; IMMUNOPATHOLOGY; LIPIDOMICS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; METABOLOMICS; NONHUMAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84946589786     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2015-000087     Document Type: Review

References (25)

1. Poon IK, Lucas CD, Rossi AG, et al. Apoptotic cell clearance: basic biology and therapeutic potential. Nature Reviews Immunol 2014;14:166-80.
2. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011;13:202.
3. Vanarsa K, Mohan C. Proteomics in rheumatology: The dawn of a new era. F1000 Med Rep 2010;2:87.
4. Nowling TK, Mather AR, Thiyagarajan T, et al. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. J Am Soc Nephrol 2014. Published Online First: 30 Sept 2014. doi: 10.1681/ASN.2014050508.
5. Franklin BS, Bossaller L, De Nardo D, et al. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat Immunol 2014;15:727-37.
6. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007;56:2344-51.
7. Heinlen LD, McClain MT, Ritterhouse LL, et al. 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS ONE 2010;5: e9599.
8. Eriksson C, Kokkonen H, Johansson M, et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13:R30.
9. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
10. Arbuckle MR, James JA, Kohlhase KF, et al. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001;54:211-19.
11. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007;16:401-9.
12. Olsen NJ, Yousif M, Mutwally A, et al. Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatol Int 2013;33:2585-90.
13. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:775-84.
14. Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-22.
15. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination. Semin Arthritis Rheum 1989;18:282-96.
16. Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: An appareRnt advantage of quinacrine. Int J Dermatol 1981;20:57-61.
17. Tye MJ, White H, Appel B, et al. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. NEJM 1959;260:63.
18. Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: A prospective analysis. Arch Dermatol 2011;147:1261-7.
19. Panopalis P, Gillis JZ, Yazdany J, et al. Frequent use of the emergency department among persons with systemic lupus erythematosus. Arthritis Care Res 2010;62:401-8.
20. Yazdany J, Feldman CH, Liu J, et al. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res 2014;66:617-24.
21. [No author listed]. Survey: ED physicians report burnout, desire help for dealing with frequent users. ED Manag 2011;23:104-5.
22. LaCalle E, Rabin E. Frequent users of emergency departments: The myths, the data, and the policy implications. Ann Emerg Med 2010;56:42-8.
23. Byrne M, Murphy AW, Plunkett PK, et al. Frequent attenders to an emergency department: A study of primary health care use, medical profile, and psychosocial characteristics. Ann Emerg Med 2003;41:309-18.
24. http://en.wikipedia.org/wiki/It%27s-the-economy,-stupid (accessed Dec 2014).
25. Maddison PJ, Reichlin M. Quantitation of precipitating antibodies to certain soluble nuclear antigens in SLE. Arthritis Rheum 1977;20:819-24.